Combining GLP-1 Agonists With DPP-4 Inhibitors Offers Little Extra Benefit for Diabetes
Combining a GLP-1 receptor agonist with a DPP-4 inhibitor provides only a small additional reduction in HbA1c and weight, which is unlikely to justify the potential increased pancreatitis risk and added cost.
Quick Facts
What This Study Found
Combining GLP-1 RA and DPP-4 inhibitor provides only a small incremental reduction in HbA1c and weight loss, with the benefit unlikely to offset potential pancreatitis risk and additional cost.
Key Numbers
6 studies from 1,255 screened; small additional HbA1c and weight benefit; hypoglycemia, GI, pancreatitis infrequent
How They Did This
Systematic literature review across five databases (1946-2020). Six studies meeting criteria analyzed for efficacy (HbA1c, weight) and safety (hypoglycemia, GI upset, pancreatitis).
Why This Research Matters
Clinicians sometimes encounter patients on both drug classes, and understanding whether this combination is worthwhile prevents unnecessary polypharmacy, cost, and potential safety risks.
The Bigger Picture
Both GLP-1 RAs and DPP-4 inhibitors work through the incretin system, so combining them targets overlapping mechanisms. This review confirms the pharmacological expectation that adding a DPP-4 inhibitor to a GLP-1 RA — which already maximally activates GLP-1 receptors — yields diminishing returns.
What This Study Doesn't Tell Us
Only 6 studies met criteria, limiting the evidence base. Heterogeneity across studies in drug combinations, doses, and populations. Long-term outcomes not assessed.
Questions This Raises
- ?Should patients on dual incretin therapy be deprescribed to monotherapy?
- ?Are there specific patient subgroups who might benefit from combination incretin therapy?
- ?How does combination incretin therapy compare to GLP-1 RA plus SGLT2 inhibitor?
Trust & Context
- Key Stat:
- Small incremental benefit only 6 studies show combination incretin therapy doesn't meaningfully improve outcomes beyond GLP-1 RA monotherapy
- Evidence Grade:
- Systematic review limited by the small number of qualifying studies (n=6). Provides moderate-quality evidence against combination incretin therapy.
- Study Age:
- Published in 2021, with database searches through April 2020.
- Original Title:
- Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.
- Published In:
- Journal of clinical pharmacy and therapeutics, 46(1), 28-34 (2021)
- Authors:
- Cowart, Kevin(2), Updike, Wendy H, Lloyd, Andie, Bullers, Krystal
- Database ID:
- RPEP-05329
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Should I take both a GLP-1 drug and a DPP-4 inhibitor for diabetes?
This review suggests the combination isn't worth it. Since both drugs work through similar pathways, adding a DPP-4 inhibitor to a GLP-1 receptor agonist provides only a small additional benefit in blood sugar control — likely not enough to justify the extra cost and potential risks.
What's a better combination than dual incretin therapy?
Current evidence supports combining a GLP-1 receptor agonist with an SGLT2 inhibitor (like empagliflozin or dapagliflozin), which works through a completely different mechanism and provides complementary cardiovascular and kidney benefits.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05329APA
Cowart, Kevin; Updike, Wendy H; Lloyd, Andie; Bullers, Krystal. (2021). Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.. Journal of clinical pharmacy and therapeutics, 46(1), 28-34. https://doi.org/10.1111/jcpt.13270
MLA
Cowart, Kevin, et al. "Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.." Journal of clinical pharmacy and therapeutics, 2021. https://doi.org/10.1111/jcpt.13270
RethinkPeptides
RethinkPeptides Research Database. "Anticipatory guidance and systematic review of prescribing c..." RPEP-05329. Retrieved from https://rethinkpeptides.com/research/cowart-2021-anticipatory-guidance-and-systematic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.